Ausgabe Sonderheft 1/2012
Supplement Issue: Optimize Project: Recommendations of the currently management in metastatic Renal Cell Carcinoma
Inhalt (6 Artikel)
The optimize project: beyond first-line therapy in metastatic renal cell carcinoma
Daniel Castellano, Joaquim Bellmunt
Evaluation of patients with metastatic renal cell carcinoma after failure of first-line treatment
Joan Carles, Isabel Chirivella, Miguel Ángel Climent, Enrique Gallardo, Arancha González del Alba, José Pablo Maroto, Begoña Mellado, Francisco Xavier García del Muro
Sequential therapy in metastatic renal cell carcinoma: pre-clinical and clinical rationale for selecting a second- or subsequent-line therapy with a different mechanism of action
José Luís González Larriba, Enrique Espinosa, Icíar García Carbonero, Javier García-Donas, María López, Andrés Meana, Javier Puente, Joaquim Bellmunt
Management of adverse events of targeted therapies in normal and special patients with metastatic renal cell carcinoma
María José Méndez-Vidal, Esther Martínez Ortega, Álvaro Montesa Pino, Begoña Pérez Valderrama, Ruth Viciana
The role of pharmacogenomics in metastatic renal cell carcinoma
Daniel Castellano, Juan Antonio Virizuela, Josefina Cruz, Juan Manuel Sepulveda, Maribel Sáenz, Luís Paz-Ares
Quality of life and supportive care for patients with metastatic renal cell carcinoma
Julio Lambea, Carmen Hinojo, Nuria Lainez, Martín Lázaro, Luís León, Ángel Rodríguez, Diego Soto de Prado, Emilio Esteban